Nuvalent

At Nuvalent, Inc., we are at the forefront of oncological innovation, dedicated to creating precisely targeted therapies that address the significant unmet needs of cancer patients. Leveraging our deep expertise in chemistry and state-of-the-art structure-based drug design, we are revolutionizing the development of novel small molecules. Our innovative approach focuses on engineering therapies with exquisite target selectivity, a critical factor in overcoming drug resistance, minimizing adverse events often associated with less targeted treatments, and effectively addressing brain metastases, a common and challenging complication in many cancers. We believe this precision is key to driving more durable and meaningful responses for patients, ultimately transforming their treatment journeys and outcomes.

Our robust pipeline features parallel lead programs targeting ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), two areas where existing therapies have limitations. Beyond these advanced programs, Nuvalent is actively pursuing multiple discovery-stage research initiatives, continually seeking new clinically proven kinase targets. This relentless pursuit of scientific advancement underscores our commitment to expanding the frontiers of cancer treatment. Our team, comprised of experienced scientists and industry veterans, is driven by a shared passion for patient impact, empowerment, and collaboration. These core values guide our daily work as we strive to translate groundbreaking scientific insights into tangible therapeutic options that can make a profound difference in the lives of those affected by cancer. We are committed to not only advancing our current programs but also to fostering a culture of continuous innovation to tackle the evolving challenges in oncology.